ArticleFrontiers in immunology2025
Screening and identification of human HPV18VLP neutralizing antibodies from women receiving HPV vaccine.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vaginal Microecological Imbalance, Human Papillomavirus Infection, and Cervical Carcinogenesis: Mechanisms and Clinical Implications.International journal of general medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, the primary treatments for cervical cancer patients are surgery or chemoradiotherapy, with a lack of standardized pharmacological therapies. Here, we report the construction of a Fab fragment phage display antibody library with a capacity of 10^9, derived from peripheral blood mononuclear cells of 15 women vaccinated against HPV. Through four rounds of screening, one clone, VLP18-Fab, specifically binding to HPV18 virus-like particles (HPV18 VLP), was selected from 40 clones. Additionally, the VLP18-Fab antibody demonstrated a highly significant and dose-dependent neutralizing activity against HPV18 pseudoviruses (P < 0.0001).Moreover,following identification, the structure of the antibody-antigen binding complex was simulated using BIOVIA Discovery Studio, which included the identification of potential binding sites. Overall, this study underscores the potential of phage-displayed antibody library technology for screening neutralizing antibodies and provides valuable insights for the design of HPV vaccines based on structural studies of antigen-antibody complexes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.